Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;117(1):41-47.
doi: 10.1097/AOG.0b013e318202ac23.

Effect of injectable and oral contraceptives on glucose and insulin levels

Affiliations

Effect of injectable and oral contraceptives on glucose and insulin levels

Abbey B Berenson et al. Obstet Gynecol. 2011 Jan.

Abstract

Objective: To estimate the effect of using two methods of hormonal contraceptives (depot medroxyprogesterone acetate) or an oral contraceptive pill (OCP) containing 20 micrograms ethinyl estradiol and 0.15 mg desogestrel) on serum glucose and insulin levels, as well as predictors of any observed changes.

Methods: Fasting glucose and insulin levels were measured on 703 white, African-American, and Hispanic women using depot medroxyprogesterone acetate, OCPs, or nonhormonal birth control at baseline and every 6 months thereafter for 3 years. Participants also completed questionnaires containing demographic and behavioral measures every 6 months. Mixed-model regression analyses were used to estimate changes over time in glucose and insulin levels by method, along with their predictors.

Results: Depot medroxyprogesterone acetate, but not OCP, users experienced slightly greater increases in glucose and insulin as compared with nonhormonal users (P<.001). Among depot medroxyprogesterone acetate users, a small but steady increase in serum glucose levels (2 mg/dL at 6 months to 3 mg/dL at 30 months) was observed throughout the first 30 months, but it leveled off after that. In contrast, serum insulin levels showed an upward (3 units at 6 months to 4 units at 18 months) trend for the first 18 months of depot medroxyprogesterone acetate use and then remained almost flat thereafter. Elevation of insulin and glucose levels was slightly more pronounced in obese and overweight depot medroxyprogesterone acetate users than those who were normal weight.

Conclusion: Use of depot medroxyprogesterone acetate, but not very-low-dose OCPs containing desogestrel, can lead to slightly higher fasting glucose and insulin levels.

Level of evidence: II.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no conflicts of interest or disclosures.

Figures

Figure 1
Figure 1
Modeled mean change of blood glucose and serum insulin from baseline across 36 months by contraceptive method. Empty circles: nonhormonal contraceptives; X shape: oral contraceptives; solid triangles: depot medroxyprogesterone acetate. Solid lines represent the estimated mean changes, and dotted lines represent the unadjusted values.
Figure 2
Figure 2
Modeled mean change of blood glucose and serum insulin from baseline across 36 months by contraceptive method and body mass index status (A), blood glucose – normal weight, (B) blood glucose – overweight (C), blood glucose – obese, (D) serum insulin –normal weight (E) serum insulin –overweight, and (F) serum insulin –obese. Empty circles: nonhormonal contraceptives; X shape: oral contraceptives; solid triangles: depot medroxyprogesterone acetate.

Similar articles

Cited by

References

    1. Sangi-Haghpeykar H, Poindexter AN, III, Bateman L, Ditmore JR. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol. 1996;88:227–33. - PubMed
    1. Cromer BA, Smith RD, Blair JM, Dwyer JT, Brown RT. A prospective study of adolescents who choose among levonorgestrel im- plant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics. 1994;94:694. - PubMed
    1. Berenson AB, Odom SD, Breitkopf CR, Rahman M. Physiologic and psychologic symptoms associated with use of injectable contraception and 20 μg oral contraceptive pills. Am J Obstet Gynecol. 2008;199:351, e1–12. - PMC - PubMed
    1. Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86:1466–74. - PubMed
    1. Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol. 2008 Oct;112(4):788–99. - PMC - PubMed

Publication types